A systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3cm

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 5, 2013, Pages 793-800

  Shen, Ai ^a   Zhang, Hua ^b   Tang, Chengyong ^a   Chen, Yong ^a   Wang, Yefei ^a   Zhang, Chao ^a   Wu, Zhongjun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b People's Hospital of Changshou District   (China)

Author keywords

Percutaneous ethanol injection; Radiofrequency ablation; Randomized controlled trial; Systematic review

Indexed keywords

ALCOHOL;

ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHILD PUGH SCORE; COCHRANE LIBRARY; COST BENEFIT ANALYSIS; EMBASE; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER FUNCTION; MEDLINE; META ANALYSIS; METASTASIS; OVERALL SURVIVAL; PERCUTANEOUS ETHANOL INJECTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; SYSTEMATIC REVIEW; TUMOR NECROSIS; TUMOR VOLUME;

EID: 84876997813     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12162     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108.
2. Dusheiko GM, Hobbs KE, Dick R, Burroughs AK. Treatment of small hepatocellular carcinomas. Lancet 1992; 340: 285-288.
3. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N. Engl. J. Med. 2007; 356: 1545-1559.
4. Surman OS, Hertl M. Liver donation: donor safety comes first. Lancet 2003; 362: 674-675.
5. Singer PA, Siegler M, Whitington PF etal. Ethics of liver transplantation with living donors. N. Engl. J. Med. 1989; 321: 620-622.
6. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J. Hepatol. 2010; 52: 380-388.
7. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773.
8. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 353-357.
9. Huang G-T, Lee P-H, Tsang Y-M etal. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann. Surg. 2005; 242: 36-42.
10. Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009; 9: 31.
11. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 2009; 104: 514-524.
12. Omata M, Lesmana LA, Tateishi R etal. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 2010; 4: 439-474.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
14. Giorgio A. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis: a simple, effective and cheap procedure for percutaneous ablation. J. Gastrointestin. Liver Dis. 2010; 19: 461-462.
15. Forner A, Bruix J. Ablation for hepatocellular carcinoma: is there need to have a winning technique? J. Hepatol. 2010; 52: 310-312.
16. Brunello F, Veltri A, Carucci P etal. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand. J. Gastroenterol. 2008; 43: 727-735.
17. Giorgio A, Di Sarno A, De Stefano G etal. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011; 31: 2291-2295.
18. Lencioni R, Pinto F, Armillotta N etal. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur. Radiol. 1997; 7: 514-519.
19. Ishii H, Okada S, Nose H etal. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996; 77: 1792-1796.
20. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998; 27: 67-72.
21. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 1998; 17: 2815-2834.
23. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
24. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less. Gut 2005; 54: 1151-1156.
25. Shiina S, Teratani T, Obi S etal. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986; 7: 177-188.
27. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob. Agents Chemother. 2004; 48: 2787-2792.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21: 1539-1558.
30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
32. Schünemann H, Brozek J, Oxman A, eds. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group. 2009. Cited 5 Nov 2012. Available from URL: http://www.cc-ims.net/gradepro
33. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451.
34. Lencioni RA, Allgaier HP, Cioni D etal. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
35. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4cm. Gastroenterology 2004; 127: 1714-1723.
36. Azab M, Zaki S, El-Shetey AG etal. Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma. Arab J. Gastroenterol. 2011; 12: 113-118.
37. Morimoto O, Nagano H, Sakon M etal. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J. Hepatol. 2003; 39: 215-221.
38. Imamura H, Matsuyama Y, Tanaka E etal. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 2003; 38: 200-207.
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
40. Yu NC, Chaudhari V, Raman SS etal. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 2011; 9: 161-167.
41. Orloff MJ, Isenberg JI, Wheeler HO etal. A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. Am. J. Surg. 2012; 203: 182-190.
42. Llovet JM, Vilana R, Bru C etal. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33: 1124-1129.
43. Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Hepatogastroenterology 2001; 48: 20-24.
44. Steels E, Paesmans M, Berghmans T etal. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. J. 2001; 18: 705-719.
45. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-459.
46. Moher D, Pham B, Klassen TP etal. What contributions do languages other than English make on the results of meta-analyses? J. Clin. Epidemiol. 2000; 53: 964-972.
47. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.